Teligent (TLGT) Announces William S. Marth to Board

February 16, 2021 7:42 AM EST
Get Alerts TLGT Hot Sheet
Price: $0.56 +7.69%

Overall Analyst Rating:
    NEUTRAL (Up Up)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Teligent, Inc. (NASDAQ: TLGT) today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries.

John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and achieve their potential. Following the strategic steps we announced earlier this year to strengthen the Company's balance sheet and position the business for success, we have reached a critical time in Teligent's journey where Bill's innovative thinking will be invaluable. We are confident that the appointment of Bill, along with the existing members of our Board, will help ensure that Teligent has strong Board leadership as the company works to execute on its strategic plans going forward."

Mr. Marth currently serves as the Managing Partner of North Ocean Ventures, LLC, a consulting firm that helps pharmaceutical businesses realize their full potential, and most recently served as the Global President and Chief Executive Officer of North America & Europe of Avet Pharma Holdings Inc., a specialty generic pharmaceutical company and subsidiary of Emcure Pharmaceuticals Ltd. Previously, Mr. Marth served as the President and CEO of Albany Molecular Research, Inc. (AMRI), a global contract research and manufacturing company providing services to the pharmaceutical and biotechnology industries. Before that, Mr. Marth served in various senior leadership roles at Teva Pharmaceutical Industries Limited, including President and CEO of Teva Pharmaceuticals – Americas, as well as CEO of Teva North America and CEO of Teva USA, while also serving as a member of Teva's global executive management team.

Notably, after a series of seven acquisitions in four years Mr. Marth built AMRI into one of the top five global contract development and manufacturing organizations with revenues in excess of $700 million, after which Mr. Marth led the take-private of AMRI in September of 2017 in a $1.6 billion transaction. Additionally, Mr. Marth played a critical role in the expansion of Teva Pharmaceuticals in the Americas from 1999 – 2012.

Mr. Marth said, "I am pleased to join Teligent's Board of Directors at this exciting time of revitalization and potential growth for the Company. Teligent's products and reputation as a quality manufacturer are known throughout the industry, and I am looking forward to working with management and the Board to grow Teligent's business and maximize the Company's position in the generic pharmaceutical, product development and contract manufacturing marketplaces."

Mr. Marth holds a Bachelor of Science in Pharmacy from the University of Illinois College of Pharmacy, a Master's in Business Administration from the Keller Graduate School of Management, DeVry University, and an honorary Doctor of Humane Letters from the Albany College of Pharmacy and Health Sciences.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News, Management Comments